Taxanes in primary systemic treatment of breast cancer;Taxane in der primären systemischen therapie des mammakarzinoms

Onkologie

Volumn 26, Issue SUPPL. 7, 2003, Pages 21-25

  Von Minckwitz, G ^a,b  

^a German Breast Group   (Germany)

^b German Breast Group   (Germany)

Author keywords

Breast cancer; Docetaxel; Primary systemic therapy

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; FLUOROURACIL; METHOTREXATE; PACLITAXEL; TAXANE DERIVATIVE;

ADJUVANT THERAPY; BREAST CANCER; CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; HUMAN; PHARMACOGENOMICS; POSTOPERATIVE CARE; REVIEW; TECHNIQUE; TUMOR CELL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; HUMANS; MASTECTOMY, SEGMENTAL; NEOPLASM STAGING; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS; SURVIVAL RATE; TAXOIDS; TREATMENT OUTCOME;

EID: 0346970955     PISSN: 0378584X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (15)

1. Kaufmann M, von Minckwitz G, Smith R, Valero V, Gianni L, Eiermann W, Howell A, Costa SD, Beuzeboc P, Untch M, Blohmer JU, Sinn HP, Sittek R, Souchon R, Tulusan AH, Volm T, Senn HJ: International consensus panel on the primary systemic treatment of breast cancer - meeting highlights and recommendations. J Clin Oncol 2003;21:2600-2608.
2. www.ago-online.de
3. NSABP: The effect on primary tumor response of adding sequential taxotere to adriamycin and cyclophosphamide: Preliminary results of the NSABP protocol B-27. Breast Cancer Res Treat 2001;69:210(abstract 5) [updated with personal communications].
4. von Minckwitz G, Raab G, Schütte M, Hilfrich J, Blohmer JU, Gerber B, Costa SD, Merkle E, Eidtmann H, Lampe W, Jackisch C, duBois A, Caputo A, Kaufmann M: Dose-dense versus sequential adriamcycin/docetaxel combination as preoperative chemotherapy (pCHT) in operable breast cancer (T2-3, N0-2, M0) - primary endpoint analysis of the Geparduo-Study. Proc ASCO 2002.
5. von Minckwitz G, Costa SD, Eiermann W, Blohmer JU, Tulusan AH, Jackisch C, Kaufmann M: Maximized reduction of primary breast tumor size using preoperative chemotherapy with adriamycin and docetaxel. J Clin Oncol 1999;17:1999-2005.
6. von Minckwitz G, Costa SD, Raab G, Blohmer U, Eidtmann H, Hilfrich J, Merkle E, Jackisch C, Gademann G, Tulusan AH, Eiermann W, Graf E, Kaufmann M: Dose-dense doxorubicin, docetaxel, and granulocyte colony-stimulating factor support with or without tamoxifen as preoperative therapy in patients with operable carcinoma of the breast: A randomized, controlled, open phase IIb study. J Clin Oncol 2001;19:3506-3515.
7. Gianni L, Baselga J, Eiermann W, Porta VG, Semiglazov V, Garcia-Conde J, Zambetti M, Valagussa P, Bonadonna G: First report of the European Cooperative Trial in operable breast cancer (ECTO): Effects of primary systemic therapy (PST) on local-regional disease. Proc ASCO 2002.
8. Untch M, Konecny G, Ditsch N, Sorokina Y, Moebus V, Muck B, Kuhn W, Bastert G, Werner C, Thomssen C, Wallwiener D, Albert U, Bothmann G, Kreienberg R, Lück HJ: Dose-dense sequential epirubicin-paclitaxel as preoperative treatment of breast cancer: Results of a randomised AGO study. Proc ASCO 2002: abstr 133.
9. von Minckwitz G, Brunnert K, Costa SD, Friedrichs K, Jackisch C, Gerber B, Harbeck N, Junkermann H, Mobus V, Nitz U, Schaller G, Scharl A, Thomssen C, Untch M: Evidence-based recommendations on primary treatment of carcinomas of the breast. Zentralbl Gynakol 2002;124:293-303 (aktualisierte Version unter www.ago-on-line.de).
10. von Minckwitz G, Sinn HP, Petrich S, Raab G, Blohmer JU, Caputo A, Kaufmann M. Clinical response after two cycles is superior to HER2, Ki-67, p53, and bcl-2 in independently predicting a pathological complete response after peroperative chemotherapy in patients with operable carcinoma of the breast. Eur J Cancer 2002;38(suppl 3):107.
11. Verrill MV, nn: Breat Cancer Res Treat 1998;50:328.
12. Khayat D: ASCO 2001 Educational Book nn.
13. Smith IC, Heys SD, Hutcheon AW, Miller ID, Payne S, Gilbert FJ, Ah-See AK, Eremin O, Walker LG, Sarkar TK, Eggleton SP, Ogston KN: Neoadjuvant chemotherapy in breast cancer: Significantly enhanced response with docetaxel. J Clin Oncol 2002;20:1456-1466.
14. von Minckwitz G, Blohmer JU, Löhr A, Gerber B, Raab G, Eidtmann H, Hilfrich J, Merkle E, Jackisch C, Costa SD, Schütte M, Kaufmann M: In-vivo-chemosensitivity adapted preoperative chemotherapy in patients with primary operable breast cancer. First experiences of the pilot Gepartriostudy. Breast Canc Res Treat 2002;76(suppl 1):51.
15. Goldhirsch A, Glick JH, Gelber RD, Coates AS, Senn HJ: Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. Seventh International Conference on Adjuvant Therapy of Primary Breast Cancer. J Clin Oncol. 2001;19:3817-3827.